SCHEMBL5336669

SCHEMBL5336669

COc1cc(Nc2ncnc3sc(-c4ccccc4)c(C)c23)cc(OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.54
HTT P42858 3/20 0.54
MAPK1 P28482 3/20 0.54
HPGD P15428 2/20 0.54
TP53 P04637 1/20 0.54
FGFR1 P11362 3/20 0.53
LIMK1 P53667 1/20 0.52
ALDH1A1 P00352 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
CYP1A2 P05177 1/20 0.51
GLA P06280 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
KMT2A Q03164 1/20 0.51
LMNA P02545 2/20 0.48
RAF1 P04049 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5467444 0.84 MAPT (0.64) MAPTHTTMAPK1HPGDTP53
Hydrochloric Acid SCHEMBL5452785 0.83 MAPT (0.63) MAPTHTTMAPK1HPGDFGFR1
SCHEMBL5453676 0.82 MAPT (0.63) MAPTHTTMAPK1HPGDTP53
SCHEMBL5334693 0.72 TP53 (0.68) MAPTHTTMAPK1HPGDTP53
SCHEMBL423214 0.72 LIMK1 (0.72) MAPTHTTMAPK1HPGDFGFR1
SCHEMBL15426163 0.71 FGFR1 (0.67) FGFR1LMNAMKNK1CLK1RAB9A
SCHEMBL13164963 0.71 MAPK1 (1.00) MAPTHTTMAPK1HPGDFGFR1
SCHEMBL5467523 0.70 RAB9A (0.76) MAPTHTTMAPK1HPGDTP53
SCHEMBL4765789 0.69 LIMK1 (0.68) MAPTHTTMAPK1HPGDFGFR1
SCHEMBL5315096 0.68 RAB9A (0.79) MAPTMAPK1TP53ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007056215-A9 N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF CYTOVIA INC (US) 2007-09-13 WO disclosed
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099877-A1 N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP4, CASP3, API5 MAPT 4267/4885HTT 2713/4885MAPK1 2419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.